ARTV Stock Forecast & Price Target

Artiva Biotherapeutics is supported by compelling early clinical data showing AlloNK generated deep, reproducible responses across refractory RA and Sjögren’s disease, including 71% ACR50 at 6 months in RA and meaningful improvements in ClinESSDAI, ESSPRI, and salivary flow in SjD. The program’s differentiated safety profile, with no CRS, ICANS, GvHD, or hypogammaglobulinemia reported across the 73-patient dataset, strengthens the case for broad outpatient and community use versus more intensive cell therapies. Its outlook is further reinforced by a pro-forma cash position of $387M, expected runway well into 2028, and an upcoming ~150-patient registrational RA study that could validate a scalable off-the-shelf platform.

Artiva Biotherapeutics is viewed negatively because its lead asset AlloNK remains in early development, with all clinical programs at Phase II or earlier and no assurance of success, especially given the stated bear case that it may fail to produce durable remissions or may be poorly tolerated. The competitive backdrop is crowded with multiple active cell therapy rivals and emerging bispecifics, while no NK cell therapy has yet been approved by the FDA or EMA, increasing the risk that Artiva may struggle to gain market share or secure regulatory clearance. Financially, the company is expected to require additional funding to advance candidates through trials and toward launch, and there is no guarantee that financing will be available on favorable terms.